AR016751A1 - METHOD FOR INHIBITING THE RELEASE OF THE BETA-AMYLOID PEPTIDE IN A CELL, PHARMACEUTICAL COMPOSITION AND USEFUL COMPOUNDS IN THIS METHOD - Google Patents
METHOD FOR INHIBITING THE RELEASE OF THE BETA-AMYLOID PEPTIDE IN A CELL, PHARMACEUTICAL COMPOSITION AND USEFUL COMPOUNDS IN THIS METHODInfo
- Publication number
- AR016751A1 AR016751A1 ARP970105393A ARP970105393A AR016751A1 AR 016751 A1 AR016751 A1 AR 016751A1 AR P970105393 A ARP970105393 A AR P970105393A AR P970105393 A ARP970105393 A AR P970105393A AR 016751 A1 AR016751 A1 AR 016751A1
- Authority
- AR
- Argentina
- Prior art keywords
- beta
- release
- inhibiting
- cell
- pharmaceutical composition
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 2
- 238000003786 synthesis reaction Methods 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06043—Leu-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Se describen compuestos que inhiben la liberacion de péptidos Beta-amiloides y/o sus síntesis, y por consiguiente que tienen utilidad paratratar la enfermedad de Alzheimer. Asimismo se describen composiciones farmacéuticas quecomprende un compuesto que inhibe la liberacion de péptidosBeta-amiloides y/o sus síntesis así como también métodos para tratar la enfermedad de Alzheimer tanto profiláctica como terapéuticamente con dichascomposiciones farmacéuticas.Compounds that inhibit the release of beta-amyloid peptides and / or their syntheses are described, and therefore have utility to treat Alzheimer's disease. Also described are pharmaceutical compositions comprising a compound that inhibits the release of Beta-amyloid peptides and / or their syntheses as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with said pharmaceutical compositions.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75544296A | 1996-11-22 | 1996-11-22 | |
| US80742797A | 1997-02-28 | 1997-02-28 | |
| US80752897A | 1997-02-28 | 1997-02-28 | |
| US80852897A | 1997-02-28 | 1997-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR016751A1 true AR016751A1 (en) | 2001-08-01 |
Family
ID=27505670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970105393A AR016751A1 (en) | 1996-11-22 | 1997-11-18 | METHOD FOR INHIBITING THE RELEASE OF THE BETA-AMYLOID PEPTIDE IN A CELL, PHARMACEUTICAL COMPOSITION AND USEFUL COMPOUNDS IN THIS METHOD |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP0942924A2 (en) |
| JP (1) | JP2001503782A (en) |
| KR (1) | KR20000069064A (en) |
| CN (1) | CN1238779A (en) |
| AR (1) | AR016751A1 (en) |
| AU (1) | AU5356198A (en) |
| BR (1) | BR9713400A (en) |
| CA (1) | CA2267634A1 (en) |
| CO (1) | CO4910156A1 (en) |
| CZ (1) | CZ122899A3 (en) |
| EA (1) | EA199900490A1 (en) |
| HR (1) | HRP970627A2 (en) |
| HU (1) | HUP0100270A3 (en) |
| ID (1) | ID22044A (en) |
| IL (1) | IL129083A0 (en) |
| NO (1) | NO992368L (en) |
| NZ (1) | NZ334690A (en) |
| PE (1) | PE16999A1 (en) |
| TR (3) | TR199902937T2 (en) |
| WO (1) | WO1998022494A2 (en) |
| YU (1) | YU46097A (en) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122010000020I1 (en) | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Method for lowering the blood glucose level in mammals |
| US6191166B1 (en) * | 1997-11-21 | 2001-02-20 | Elan Pharmaceuticals, Inc. | Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis |
| US6635632B1 (en) | 1996-12-23 | 2003-10-21 | Athena Neurosciences, Inc. | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
| DE19823831A1 (en) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | New pharmaceutical use of isoleucyl thiazolidide and its salts |
| CA2325389A1 (en) * | 1998-06-22 | 1999-12-29 | James E. Audia | Compounds for inhibiting beta-amyloid peptide release and/or its synthesis |
| US6552013B1 (en) | 1998-06-22 | 2003-04-22 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
| US6958330B1 (en) | 1998-06-22 | 2005-10-25 | Elan Pharmaceuticals, Inc. | Polycyclic α-amino-ε-caprolactams and related compounds |
| CA2324475A1 (en) * | 1998-06-22 | 1999-12-29 | Elan Pharmaceuticals, Inc. | Cyclic amino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting .beta.-amyloid peptide release and/or its synthesis by use of such compounds |
| JP2002518481A (en) * | 1998-06-22 | 2002-06-25 | エラン ファーマシューティカルズ，インコーポレイテッド | Compounds for inhibiting the release of β-amyloid peptide and / or its synthesis |
| DE19828114A1 (en) | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs of unstable inhibitors of dipeptidyl peptidase IV |
| DE19828113A1 (en) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs of Dipeptidyl Peptidase IV Inhibitors |
| DE19834591A1 (en) | 1998-07-31 | 2000-02-03 | Probiodrug Ges Fuer Arzneim | Use of substances that decrease the activity of dipeptidyl peptidase IV to increase blood sugar levels, e.g. for treating hypoglycemia |
| AU6278099A (en) | 1998-09-30 | 2000-04-17 | Elan Pharmaceuticals, Inc. | Biological reagents and methods for determining the mechanism in the generation of beta-amyloid peptide |
| US6737038B1 (en) | 1998-11-12 | 2004-05-18 | Bristol-Myers Squibb Company | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging |
| JP2002531576A (en) | 1998-12-10 | 2002-09-24 | エフ．ホフマン−ラ ロシュ アーゲー | Procollagen C-proteinase inhibitor |
| EP1189881B2 (en) * | 1999-05-07 | 2013-01-23 | Encysive Pharmaceuticals, Inc. | Propanoic acid derivatives that inhibit the binding of integrins to their receptors |
| US6723711B2 (en) | 1999-05-07 | 2004-04-20 | Texas Biotechnology Corporation | Propanoic acid derivatives that inhibit the binding of integrins to their receptors |
| US6972296B2 (en) | 1999-05-07 | 2005-12-06 | Encysive Pharmaceuticals Inc. | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
| DE19926233C1 (en) | 1999-06-10 | 2000-10-19 | Probiodrug Ges Fuer Arzneim | Production of thiazolidine, useful as pharmaceutical intermediate, comprises reacting hexamethylenetetramine with cysteamine |
| DE19940130A1 (en) | 1999-08-24 | 2001-03-01 | Probiodrug Ges Fuer Arzneim | New effectors of Dipeptidyl Peptidase IV for topical use |
| AU1569401A (en) * | 1999-11-09 | 2001-06-06 | Eli Lilly And Company | Beta-aminoacid compounds useful for inhibiting beta-amyloid peptide release and/or its synthesis |
| WO2001072290A2 (en) | 2000-03-31 | 2001-10-04 | Probiodrug Ag | Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
| AU2001261728A1 (en) | 2000-05-17 | 2001-11-26 | Bristol-Myers Squibb Pharma Company | Use of small molecule radioligands for diagnostic imaging |
| CA2379445C (en) | 2000-06-01 | 2007-08-21 | Bristol-Myers Squibb Pharma Company | Lactams substituted by cyclic succinates as inhibitors of a.beta. protein production |
| FR2832152A1 (en) * | 2001-11-09 | 2003-05-16 | Aventis Pharma Sa | New 2-amino-thiazoline derivatives having inducible NO-synthase inhibiting activity, useful for treating Parkinson's, cerebral disorders, migraines, depression, diabetes |
| US6432944B1 (en) | 2000-07-06 | 2002-08-13 | Bristol-Myers Squibb Company | Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives |
| GB0016681D0 (en) | 2000-07-06 | 2000-08-23 | Merck Sharp & Dohme | Therapeutic compounds |
| US7132104B1 (en) | 2000-10-27 | 2006-11-07 | Probiodrug Ag | Modulation of central nervous system (CNS) dipeptidyl peptidase IV (DPIV) -like activity for the treatment of neurological and neuropsychological disorders |
| US6890905B2 (en) | 2001-04-02 | 2005-05-10 | Prosidion Limited | Methods for improving islet signaling in diabetes mellitus and for its prevention |
| US20030130199A1 (en) | 2001-06-27 | 2003-07-10 | Von Hoersten Stephan | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents |
| DE10150203A1 (en) | 2001-10-12 | 2003-04-17 | Probiodrug Ag | Use of dipeptidyl peptidase IV inhibitor in treatment of cancer |
| US7368421B2 (en) | 2001-06-27 | 2008-05-06 | Probiodrug Ag | Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis |
| FR2840899B1 (en) * | 2002-06-12 | 2005-02-25 | Sanofi Synthelabo | ACYLAMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THERAPEUTICS |
| AR039059A1 (en) * | 2001-08-06 | 2005-02-09 | Sanofi Aventis | COMPOUND DERIVED FROM ACILAMINOTIAZOL, ITS USE, PROCEDURES TO PREPARE IT, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, AND INTERMEDIARY COMPOUNDS |
| DE10143840A1 (en) * | 2001-09-06 | 2003-03-27 | Probiodrug Ag | New acylated hydroxamates useful for the treatment of e.g. wound healing |
| US6844316B2 (en) | 2001-09-06 | 2005-01-18 | Probiodrug Ag | Inhibitors of dipeptidyl peptidase I |
| RU2004117526A (en) | 2001-11-09 | 2005-04-10 | Авентис Фарма С.А. (Fr) | APPLICATION OF 2-AMINOTIAZOLINE DERIVATIVES AS INHIBITORS OF INDUSTRIAL NO-SYNTHASE |
| NZ534877A (en) | 2002-02-28 | 2006-05-26 | Prosidion Ltd | Glutaminyl based DPIV inhibitors |
| SG2012000667A (en) * | 2003-01-08 | 2015-03-30 | Univ Washington | Antibacterial agents |
| EP1961416B1 (en) | 2003-05-05 | 2013-01-23 | Probiodrug AG | Use of inhibitors of glutaminyl cyclase for treating psoriasis, rheumatoid arthritis or atherosclerosis. |
| ATE462432T1 (en) | 2003-05-05 | 2010-04-15 | Probiodrug Ag | GLUTAMINYL CYCLASE INHIBITORS |
| EP1666068A4 (en) * | 2003-09-24 | 2010-08-04 | Santen Pharmaceutical Co Ltd | Remedy for eye diseases accompanied by optic nerve injuries |
| KR20120007079A (en) | 2003-10-15 | 2012-01-19 | 프로비오드룩 아게 | Use of Glutaminyl and Glutamate Cycase Effectors |
| JP5539864B2 (en) | 2007-06-12 | 2014-07-02 | アカオゲン，インコーポレーテッド | Antibacterial agent |
| EP2062909A1 (en) * | 2007-11-21 | 2009-05-27 | SOLVAY (Société Anonyme) | Peptide production and purification process |
| BG110141A (en) | 2008-05-23 | 2009-12-31 | "Софарма" Ад | Galanthamine derivatives, methods for their obtaining and use |
| EP2847168A1 (en) | 2012-05-10 | 2015-03-18 | Achaogen, Inc. | Antibacterial agents |
| WO2017004560A1 (en) * | 2015-07-02 | 2017-01-05 | The Regents Of The University Of California | Methods and compositions for amyloid aggregates |
| US20240010642A1 (en) * | 2021-01-05 | 2024-01-11 | Southern Research Institute | Modulators of programmed death-ligand-1 |
| WO2024076635A2 (en) * | 2022-10-05 | 2024-04-11 | Buck Institute For Research On Aging | Suppressors of site iq electron leak and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUT62312A (en) * | 1990-03-05 | 1993-04-28 | Cephalon Inc | Process for producing chymotrypsin-like proteases and their inhibitors |
| WO1995013084A1 (en) * | 1992-05-11 | 1995-05-18 | Miles Inc. | Cathepsin d is an amyloidogenic protease in alzheimer's disease |
| CZ184194A3 (en) * | 1993-08-09 | 1995-03-15 | Lilly Co Eli | Aspartylprotease inhibitor and method of identifying thereof |
| ATE211129T1 (en) * | 1993-10-01 | 2002-01-15 | Merrell Pharma Inc | INHIBITORS OF BETA-AMYLOID PROTEIN PRODUCTION |
| US5804560A (en) * | 1995-01-06 | 1998-09-08 | Sibia Neurosciences, Inc. | Peptide and peptide analog protease inhibitors |
| US5872101A (en) * | 1995-01-06 | 1999-02-16 | Sibia Neurosciences, Inc. | Methods of treating neurodegenerative disorders using protease inhibitors |
| EP0831920A4 (en) * | 1995-06-06 | 2003-03-19 | Athena Neurosciences Inc | Novel cathepsin and methods and compositions for inhibition thereof |
-
1997
- 1997-11-18 AR ARP970105393A patent/AR016751A1/en not_active Application Discontinuation
- 1997-11-19 HR HR08/808,528A patent/HRP970627A2/en not_active Application Discontinuation
- 1997-11-20 PE PE1997001056A patent/PE16999A1/en not_active Application Discontinuation
- 1997-11-21 AU AU53561/98A patent/AU5356198A/en not_active Abandoned
- 1997-11-21 CN CN97199803A patent/CN1238779A/en active Pending
- 1997-11-21 EA EA199900490A patent/EA199900490A1/en unknown
- 1997-11-21 EP EP97950601A patent/EP0942924A2/en not_active Withdrawn
- 1997-11-21 TR TR1999/02937T patent/TR199902937T2/en unknown
- 1997-11-21 WO PCT/US1997/020804 patent/WO1998022494A2/en not_active Ceased
- 1997-11-21 JP JP52375698A patent/JP2001503782A/en active Pending
- 1997-11-21 IL IL12908397A patent/IL129083A0/en unknown
- 1997-11-21 CZ CZ991228A patent/CZ122899A3/en unknown
- 1997-11-21 NZ NZ334690A patent/NZ334690A/en unknown
- 1997-11-21 TR TR1999/02938T patent/TR199902938T2/en unknown
- 1997-11-21 CA CA002267634A patent/CA2267634A1/en not_active Abandoned
- 1997-11-21 BR BR9713400-7A patent/BR9713400A/en not_active IP Right Cessation
- 1997-11-21 YU YU46097A patent/YU46097A/en unknown
- 1997-11-21 TR TR1999/01133T patent/TR199901133T2/en unknown
- 1997-11-21 HU HU0100270A patent/HUP0100270A3/en unknown
- 1997-11-21 CO CO97068215A patent/CO4910156A1/en unknown
- 1997-11-21 ID IDW990394A patent/ID22044A/en unknown
- 1997-11-21 KR KR1019997004486A patent/KR20000069064A/en not_active Withdrawn
-
1999
- 1999-05-14 NO NO992368A patent/NO992368L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EA199900490A1 (en) | 2000-02-28 |
| TR199902938T2 (en) | 2002-06-21 |
| KR20000069064A (en) | 2000-11-25 |
| IL129083A0 (en) | 2000-02-17 |
| ID22044A (en) | 1999-08-26 |
| AU5356198A (en) | 1998-06-10 |
| PE16999A1 (en) | 1999-02-19 |
| NZ334690A (en) | 2001-09-28 |
| HUP0100270A3 (en) | 2001-09-28 |
| TR199901133T2 (en) | 1999-07-21 |
| TR199902937T2 (en) | 2001-01-22 |
| CZ122899A3 (en) | 1999-10-13 |
| EP0942924A2 (en) | 1999-09-22 |
| YU46097A (en) | 2000-10-30 |
| JP2001503782A (en) | 2001-03-21 |
| HRP970627A2 (en) | 1998-08-31 |
| CO4910156A1 (en) | 2000-04-24 |
| WO1998022494A2 (en) | 1998-05-28 |
| HUP0100270A2 (en) | 2001-08-28 |
| CA2267634A1 (en) | 1998-05-28 |
| NO992368L (en) | 1999-06-21 |
| NO992368D0 (en) | 1999-05-14 |
| BR9713400A (en) | 2000-01-25 |
| WO1998022494A3 (en) | 1998-11-26 |
| CN1238779A (en) | 1999-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR016751A1 (en) | METHOD FOR INHIBITING THE RELEASE OF THE BETA-AMYLOID PEPTIDE IN A CELL, PHARMACEUTICAL COMPOSITION AND USEFUL COMPOUNDS IN THIS METHOD | |
| BR9714517A (en) | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising them and processes to inhibit beta-amyloid peptide release and / or its synthesis by using such compounds | |
| EA199900778A1 (en) | HETEROCYCLIC COMPOUNDS AND THEIR USE TO INHIBIT β-AMYLOID PEPTIDE | |
| DE69733272D1 (en) | N- (ARYL / HETEROARYLACETYL) AMINO ACID ESTERS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF AND METHODS FOR INHIBITING THE BETA-AMYLOID EXTRACTION AND / OR THEIR SYNTHESIS USING THESE COMPOUNDS | |
| PE20020802A1 (en) | LACTAM COMPOUND AS INHIBITOR OF THE RELEASE OF THE ß-AMYLOID PEPTIDE | |
| ES2178000T3 (en) | COMPOSITIONS AND METHODS TO TREAT INFECTIONS USING INDOLICIDINE ANALOGS. | |
| MX9505182A (en) | Therapeutical composition for topical application, containing a p substance antagonist. | |
| BR9502707A (en) | Compound pharmaceutical composition and method for treating a condition | |
| ES2176600T3 (en) | DERIVATIVE OF PROPIOFENONE AND PROCEDURES FOR PREPARATION. | |
| BG101841A (en) | CELLULAR ADHESION INHIBITORS | |
| BR9714064A (en) | Pharmaceutical composition | |
| BG104599A (en) | Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas | |
| TR199701073T1 (en) | Protein kinase C inhibitors. | |
| BR9808429A (en) | Pharmaceutical composition and process for its preparation. | |
| ID29393A (en) | COMPOSITION OF CANCER TREATMENT AND METHOD OF USING NATURAL PLANT ESENSIL OILS | |
| BR9811099A (en) | Urokinase inhibitors | |
| BRPI0113286B8 (en) | substituted pyrazoles and pharmaceutical composition comprising the same. | |
| ATE264692T1 (en) | USE OF NO SYNTHASE INHIBITORS AND CAUGHTERS OF REACTIVE OXYGEN FORMS TO TREAT ISCHEMIA | |
| FI880464A0 (en) | BEKAEMPNINGSMEDEL MOT TANDPLAQUE OCH -KARIES. | |
| MX9710252A (en) | Use of one or more peptides in a cosmetic composition or for the preparation of a medicament. | |
| DK1207870T3 (en) | Pharmaceutical compositions containing N-palmitoylethanolamide and its use | |
| ES2170143T3 (en) | COMPOSITIONS THAT INCLUDE HALOFANTRINE IN A SPECIAL FORM. | |
| ES2124983T3 (en) | USE OF A SUBSTANCE P ANTAGONIST FOR THE TREATMENT OF RED SKIN STAINS OF NEUROGENOUS ORIGIN. | |
| AR004326A1 (en) | USE OF AT LEAST ONE TNF-ALPHA ANTAGONIST, COSMETIC, PHARMACEUTICAL OR DERMATOLOGICAL COMPOSITION CONTAINING SUCH ANTAGONIST AND COSMETIC DETREATMENT PROCEDURE USING SUCH ANTAGONIST. | |
| CO5060499A1 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROESOPHAGIC REFLECTION DISEASE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |